Once the arrythmia has been studied and a diagnosis made, the doctor decides what is the best therapeutic intervention in terms of safety and effectiveness. Therapeutic options include:
  • Reassuring the patient and giving them advice on how to manage irregular heartbeat if their arrythmia is benign, with no structural heart disease.
  • Drug therapy: In the event of benign arrythmia, that is when  arrythmia does not impair the patient’s lifestyle, drugs are administered in low doses in order to avoid the occurrence of any serious side-effects.
  • Transcatheter ablation: is an option for with atrial fibrillation refractory to anti-arrythmic drug therapy or when medical therapy is contra-indicated for comorbidty or intolerance.
  • Definitive pacemaker implant: is the first-line treatment for patients with severe atrioventricular block.
  • ICD: is recommendable for those patients who have malignant arrythmia that may cause sudden death.

News dal Gruppo

Il Prof. Perseghin e il Dott. Ciardullo della Medicina Metabolica del Policlinico di Monza, hanno pubblicato sulla rivista Liver International il lavoro dal titolo “Trends in prevalence of...
Il Dott. Andrea Mortara, Direttore dell’U.O. di Cardiologia del Policlinico di Monza, ha pubblicato il lavoro dal titolo “Hemodynamic effects of heart rate lowering in patients admitted...
Nell’ambito dei Seminari della Scuola di Specializzazione in Endocrinologia e Malattie del Metabolismo dell’Università degli Studi di Milano Bicocca, il 20 febbraio 2023 si terr...